

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the **ABSTRACT TEMPLATE** online, for Biomed 2025 Company Presentations

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name-**Eleven Therapeutics** * Website-**www.eleventx.com** *

CEO name-**Prof. Yaniv Erlich** *

Select a **CATEGORY: Biotech**

(Delete categories you are not selecting)

Select up to two **SESSIONS** per abstract from the list below *

(Delete sessions you are not selecting)

- **AI Meets Pharma: Building a Sustainable Value for Biotech AI innovation in Drug Development**

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

- Delivery is the main barrier to realize the power of RNA therapeutic. Backed by \$22M+ from Gates Foundation and top VCs, Eleven Therapeutics aims to transform this field.
- DELiveri®, our core platform, is a high throughput platform to discover molecules that promote cell-delivery of nucleic acids. It uses DNA-encoded libraries (DEL), synthetic biology, and AI to screen >10⁶ compounds in 3 weeks, enabling precise, non-immunogenic delivery solutions beyond the liver.
- We screened over 30 libraries in 5 different human cells, generating 200+ million data points. The platform identified a few promising hits that we validated in-vitro and in-vivo by delivering state-of-the-art RNA therapeutics.
- We have a successful partnership with Novo Nordisk on the DELiveri® platform to identify ligands that promote delivery of nucleic acids to tissues that are relevant to cardiometabolic diseases.
- Next and in addition to our partnership, we would like to establish a wholly-owned siRNA therapeutic pipeline for extra-hepatic delivery utilizing the power of our technology to address significant unmet clinical needs.